Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15501
Abstract: Several studies have compared the molecular responses between e14a2 and e13a2 BCR::ABL1 transcripts in chronic myeloid leukemia (CML) patients treated with front‐line imatinib, but there were very limited studies on nilotinib or dasatinib‐treated patients. We… read more here.
Keywords: transcripts chronic; chronic myeloid; myeloid leukemia; molecular responses ... See more keywords
Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1603.1603
Abstract: Background and Purpose: e14a2 (b3a2) and e13a2 (b2a2) are the two major BCR-ABL1 transcripts of CML. Our previous study (EHA 2016, abs P609) showed that patients with e13a2 transcripts received imatinib as front-line therapy had… read more here.
Keywords: e14a2 e13a2; molecular responses; front line; transcript subtypes ... See more keywords